Associate Professor and Head of Discovery Proteomics Facility
In the Discovery Proteomics Facility of the Target Discovery Institute we provide advice in experimental design, sample preparation, sample analysis with state-of-the-art LCMS workflows and data analysis to researchers from Oxford University and national and international collaborators. We routinely use label-free quantitation, SILAC, TMT, SWATH and other methodologies on diverse samples (i.e. cells, tissues, immuno precipitates et al.) and have developed sample preparation techniques to access the deep proteome form little sample amounts using instrumentation such as Orbitrap Fusion Lumos or TimsTOF Pro.
My own interests evolve around clinical proteomics and applications for the spatial characterisation of the proteome in biological structures such as tissues and tumours. In addition, I am developing methodologies for the proteome characterisation of clinical cohort samples at high-throughput.
Accessory ESCRT-III proteins are conserved and selective regulators of Rab11a-exosome formation.
Marie PP. et al, (2023), J Extracell Vesicles, 12
Hermansky-Pudlak syndrome type 1 causes impaired anti-microbial immunity and inflammation due to dysregulated immunometabolism.
Cavounidis A. et al, (2022), Mucosal Immunol
Biochemical and metabolic maladaption defines pathological niches in progressive multiple sclerosis
Grant-Peters M. et al, (2022)
LARP1 regulates metabolism and mTORC1 activity in cancer
Chettle J. et al, (2022)
Mapping autophagosome contents identifies interleukin-7 receptor-α as a key cargo modulating CD4+ T cell proliferation.
Zhou D. et al, (2022), Nat Commun, 13